Replies to post #177580 on Biotech Values

[ciotera]

Are GSK/THRX still developing such a product?

Do not know.. the space is getting crowded, so I wouldn't be surprised. I think it's pretty ingenious of them to push for a single device platform.

[jq1234]

Yes, GSK/THRX are still developing triple combo of ICS/LABA/LAMA. In addition, they are also to develop next generation product Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA), with both muscarinic antagonist (MA) and beta2 agonist (BA) activities in one single molecule.

AZN new acquisition Pearl Therapeutics is developing ICS/LABA/LAMA triple combo as well.